<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811313</url>
  </required_header>
  <id_info>
    <org_study_id>tranexamic acid in pediatric</org_study_id>
    <nct_id>NCT04811313</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Pediatric Undergoing Proximal Femoral Osteotomies and/or Acetabular Osteotomy</brief_title>
  <official_title>Impact of Tranexamic Acid Use on Blood Loss and Transfusion Rates After Hip Reconstruction in Children, A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgical hip reconstruction reduces the hip joint through soft tissue releases and&#xD;
      osteotomies of the femur and/or pelvis. Blood loss and subsequent blood transfusion are&#xD;
      normal consequences of hip reconstruction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the use of antifibrinolytics (AFs) to limit blood loss peri-operatively has been popularized&#xD;
      in certain subspecialties. AFs have been studied extensively in adults undergoing various&#xD;
      orthopedic procedures including spine and total joint arthroplasty, and have been proven to&#xD;
      reduce blood loss and reduce the risk of blood transfusion. Similarly, AFs are used in&#xD;
      pediatric patients undergoing cardiac surgery as well as craniofacial operations. Tranexamic&#xD;
      acid (TXA) is a synthetic anti-fibrinolytic agent that works by reversibly blocking&#xD;
      plasminogen and thereby promoting hemostasis through the prevention of fibrin degradation.&#xD;
      Current literature investigating the safety and effectiveness of TXA in children undergoing&#xD;
      orthopedic procedures is limited.&#xD;
&#xD;
      We hypothesize that patients treated with TXA will have reduced blood loss and transfusion&#xD;
      requirements compared with those who did not receive TXA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount of intraoperative blood loss</measure>
    <time_frame>24 hours</time_frame>
    <description>calculated from the fall in red blood cell volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of blood transfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>either intraoperative or postoperative blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects or complications of TXA</measure>
    <time_frame>24 hours</time_frame>
    <description>e.g. thromboembolic events or perioperative seizures will be managed and recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>24 hours</time_frame>
    <description>readiness for hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Intraoperative Blood Loss</condition>
  <condition>Pediatric</condition>
  <condition>Orthopedic Disorder</condition>
  <arm_group>
    <arm_group_label>T group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>each participant will receive 15 mg/kg of tranexamic acid diluted in a 10 mL syringe slowly over 10-15 minutes, 15 minutes before skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>each participant will receive 10 mg/kg of tranexamic acid diluted in a 5 mL syringe slowly over 5 minutes, 15 minutes before skin incision, and A caudal epidural block with 1 mL/kg of 0.25% bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>each participant will receive a caudal epidural block with 1 mL/kg of 0.25% bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will receive the regular standard care without adding tranexamic acid or caudal epidural block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA</description>
    <arm_group_label>T group</arm_group_label>
    <arm_group_label>TC group</arm_group_label>
    <other_name>Kapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>caudal epidural block</intervention_name>
    <description>regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss</description>
    <arm_group_label>C group</arm_group_label>
    <arm_group_label>TC group</arm_group_label>
    <other_name>bupivacaine 0.25%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>participants will receive standard care but neither TXA nor caudal epidural block</description>
    <arm_group_label>P group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I - II&#xD;
&#xD;
          -  Scheduled for acetabular osteotomy and/or proximal femoral derotation osteotomies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's guardian refusal to participate in the study.&#xD;
&#xD;
          -  Children known to have pre-existing bleeding or coagulation disorders.&#xD;
&#xD;
          -  Children with anemia; defined according to (WHO ) cutoffs as Hb level&lt;11g/dl for girls&#xD;
             and &lt;12g/dl for boys&#xD;
&#xD;
          -  History of epilepsy.&#xD;
&#xD;
          -  History of renal insufficiency or failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr M Sleem, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimaa A Hassan, M.D.</last_name>
    <phone>01002953253</phone>
    <email>shimaa.abbas@med.aun.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amira A Abdel-rahman, M.B.B.CH</last_name>
    <phone>01002595850</phone>
    <email>amiraali441994@gmail.com</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shimaa Abbas Hassan</investigator_full_name>
    <investigator_title>lectrure of Anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

